← Leaderboards
Mark Marino
Venturewell
$65,271,431
Attributed
$65,271,431
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $49.6M · FY2021–25$50M$37.5M$25M$12.5M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$65,271,431 · 6
By mechanism
N02$65,271,431 · 6
Top collaborators
No co-investigators on record.
Most similar at Venturewell
Same institution · by research overlap
- Rebekah Anne Neal$10,538,948
- Rebekah Neal$4,711,869
Others in their field
Other Emerging Leaders on “Commercialization”
- Joel A Lipkin · Four Points Technology, Llc$185,041,546
- Terry Drinkwine · Carahsoft Technology Corporation$94,287,243
- John E West · University Of Texas At Austin$94,000,000
- Martha Hering · Westat, Inc.$57,098,843
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Hanjoon Ryu$28,519,898
Research focus
CommercializationUnited States National Institutes Of HealthRadxInnovationPoint Of CareTechnology DevelopmentDiagnostic TestsSpeedHomeNational Institute Of Biomedical Imaging And BioengineeringProgramsServicesTechnologyFundingBaseTimelineScale UpDesignCovid-19 TestingCenters For Disease Control And Prevention (U.S.)Device DesignsCovid-19 DetectionDetection LimitExhalation
Grant awards (23)
RADx Innovation Funnel for Hepatitis B Diagnostics â Commercialization Center$2,574,898
N02 · FY2025 · HL · contact PI
RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - COMMERCIALIZATION CENTER$1,000,000
N02 · FY2025 · HL · contact PI
RADX Independent Test Assessment Program for MPOX Lesion Panel - Commercialization Center$749,977
N02 · FY2025 · HL · contact PI
NCE FOR COMMERCIALIZATION CENTER TASK ORDER FOR CANCER SCREENING RESEARCH NETWORK$528,848
N02 · FY2025 · HL · contact PI
RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - COMMERCIALIZATION CENTER$5,877,947
N02 · FY2024 · HL · contact PI
RADX INNOVATION FUNNEL FOR ENDOMETRIOSIS DIAGNOSTICS - COMMERCIALIZATION CENTER$801,749
N02 · FY2024 · HL · contact PI
NCE FOR COMMERCIALIZATION CENTER TASK ORDER FOR CANCER SCREENING RESEARCH NETWORK$528,678
N02 · FY2024 · HL · contact PI
RADX BLUEPRINT MEDTECH TRANSLATOR COHORT 1 - COMMERCIALIZATION CENTER$478,706
N02 · FY2024 · HL · contact PI
RADx Innovation Funnel for Hepatitis B Diagnostics â Commercialization Center$400,000
N02 · FY2024 · HL · contact PI
SUPPLEMENTAL FUNDS FOR RADX INDEPENDENT TEST ASSESSMENT PROGRAM FOR HEPATITIS C VIRUS - COMMERCIALIZATION CENTER$850,000
N02 · FY2023 · HL · contact PI
RADX Independent Test Assessment Program for MPOX Lesion Panel - Commercialization Center$659,763
N02 · FY2023 · HL · contact PI
NCE FOR COMMERCIALIZATION CENTER TASK ORDER FOR CANCER SCREENING RESEARCH NETWORK$528,536
N02 · FY2023 · HL · contact PI
NIBIB, INNOVATION FUNNEL FOR MATERNAL HEALTH -RADx$338,000
N02 · FY2022 · HL · contact PI
NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) INNOVATION FUNNEL FOR HIV/AIDS - COMMERCIALIZATION CENTER$306,762
N02 · FY2022 · HL · contact PI
EXERCISE OPTION PERIOD 1 TO PROVIDE SUPPORT FOR TECHNICAL ASSESSMENTS AND PROJECT MANAGEMENT FOR THE NIBIB RAPID ACCELERATION OF DIAGNOSTICS (RADX) IN$14,996,149
N02 · FY2021 · HL · contact PI
THIS IS A CONTRACT AWARD FOR VENTUREWELL TO PROVIDE SUPPORT FOR TECHNICAL ASSESSMENTS AND PROJECT MANAGEMENT FOR THE NIBIB RAPID ACCELERATION OF DIAGN$11,288,096
N02 · FY2021 · HL · contact PI
SUPPLEMENTAL FUNDS TO PROVIDE RADX INFRASTRUCTURE SUPPORT THROUGH JULY 1, 2021$7,499,311
N02 · FY2021 · HL · contact PI
RAPID ACCELERATION OF DIAGNOSTICS (RADX) CLINICAL EVALUATION SERVICES$4,625,250
N02 · FY2021 · HL · contact PI
THE PURPOSE OF THIS MODIFICATION IS TO ADD MILESTONE 1A, REVISE THE DELIVERABLES FOR MILESTONE 4-10, AND REVISE THE BASE POP TO END ON 1/18/2022.$3,179,063
N02 · FY2021 · HL · contact PI
RAPID ACCELERATION OF DIAGNOSTICS (RADX) CLINICAL EVALUATION SERVICES$2,685,235
N02 · FY2021 · HL · contact PI
THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION PERIOD 2 BY ADDING ADDING COVID-19 FUNDS FOR THE PERIOD OF PERFORMANCE OF 1/1/21 TO 4/30/21.$2,444,259
N02 · FY2021 · HL · contact PI
RAPID ACCELERATION OF DIAGNOSTICS (RADX) CLINICAL EVALUATION SERVICES$2,196,281
N02 · FY2021 · HL · contact PI
RAPID ACCELERATION OF DIAGNOSTICS (RADX) CLINICAL EVALUATION SERVICES--TASK AREA A, ADMINISTRATIVE SUPPORT$733,923
N02 · FY2021 · HL · contact PI